Bibliographic record
Abstract
IntroductionApproximately 1% of all malignancies or 10,000 cases diagnosed in North American are sarcomas.Amongst which, soft tissue sarcoma comprises of the majority.Local disease is managed with the use of pre-operative or post-operative radiation and surgery, yielding over 90% local control rate. 1 In the meta-analysis reported by Figueredo et al., 2 adjuvant chemotherapy yielded an absolute overall survival benefit of 4% and the benefit was mainly observed in tumours in the extremity, at a deep location, larger than 5 cm or high histological grade.Unfortunately, a recently reported adjuvant trial comparing doxorubicin/ifosfamide combination with observation enrolling patients with such features failed to demonstrate any overall survival benefit. 3Upon follow-up, 50% of localized soft tissue sarcomas will recur either locally, or systemically or both.The benefit of systemic therapy in the recurrent and/or metastatic setting, including doxorubicin, ifsofamide and DTIC, has been shown to be modest with an overall response rate of 10-15%, as single agent, and of 30% in combination at the expense of toxicity without any improvement to the median overall survival rate of 12 months. 4n the past 10 years, the most significant advancement has been observed in gastrointestinal stromal sarcoma (GIST), a rare form of gastrointestinal (GI) tract sarcoma.GIST originates from the interstitial cell of Cajal, a pacemaker cell in the muscularis mucosa of the GI tract. 5,6t is characterized by the expression of CD117 or c-KIT.Eighty-five to 90% of GIST harbour activating mutation in c-KIT, predominantly at exon 11 (70-75%), followed by exon 9 (10%) and rarely exons 13 and 17 (1-2%).About 5-10% of GISTs have platelet derived growth factor receptor-mutation, predominantly in exons 12 and 18. [7][8][9][10][11] The rest harbour mutation in neither tyrosine kinase receptors are considered as wild type. 7,11,12][15][16] More recently, imatinib has been licensed as adjuvant therapy for resected GIST more than 3 cm for 1 year with an improvement in progression-free survival. 17In the annual meeting of the American Society of Clinical Oncology Meeting in 2011, GISTs with c-KIT expression www.intechopen.com
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.002 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; both teacher heads agree on what is shown here.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".